FraAP
/ Sapience Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
FraAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in HNSCC models
(AACR 2025)
- "Further, in a HNSCC subcutaneous xenograft model, administration of FraAP results in significant tumor growth inhibition, demonstrating the anti-cancer potential of targeting the AP-1 complex. In summary, these data support FraAP as a potent peptide antagonist of the AP-1 transcription factor family that warrants further development as a potential therapeutic option for AP-1 driven tumors."
Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA5 • CDH1 • CDH2 • FRA1
1 to 1
Of
1
Go to page
1